Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies

Diabetic Medicine

Volumn 30, Issue 9, 2013, Pages 1026-1032

  Ferwana, M ^a,b   Firwana, B ^a,c,d   Hasan, R ^a,c,d   Al Mallah, M H ^a,b   Kim, S ^d   Montori, V M ^d   Murad, M H ^d  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c University of Missouri   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO;

BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; DRUG EXPOSURE; FAMILY HISTORY; FOLLOW UP; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SMOKING; SYSTEMATIC REVIEW; TREATMENT DURATION;

CONTROLLED CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; RISK; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84875166950     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12144     Document Type: Review

References (32)

1. Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010; 95: 2163-2171.
2. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104.
3. Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab 2009; 11: 844-854.
4. Miller JL. FDA approves pioglitazone for diabetes. Am J Health Syst Pharm 1999; 56: 1698.
5. Charbonnel B. Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials. Fundam Clin Pharmacol 2007; 21: S19-20.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
7. Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005; 48: 553-560.
8. Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin 2006; 22: S27-37.
9. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23: 1792-1823; discussion 1791.
10. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010; 113: 349-357.
11. Takeda Pharmaceuticals America Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. Available at: http://www.takeda.us/products/ Last accessed October 2012, 2009.
12. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care; 34: 1369-1371.
13. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
14. FDA. Drug Safety Communication: Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer. Rockville, MD: Food and Drug Administration, 2011.
15. La Caisse nationale de l'assurance maladie (CNAM). Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France : une étude de cohorte sur les données du SNIIRAM (Systéme National d'Information Inter-régimes de l'Assurance Maladie) et du PMSI (Programme de Médicalisation des Systémes d'Information) [Risk of bladder cancer among people with diabetes treated ethical pioglitazone in France: a cohort study from (SNIIRAM) French national health insurance information system and PMSI (French hospital discharge database). Saint Denis: Afssaps, 2011.
16. European Medicines Agency. Update on Ongoing European Review of Pioglitazone-Containing Medicines. London, UK: European Medicines Agency, 2011.
17. European Medicines Agency. European Medicines Agency Recommends New Contra-Indications and Warnings for Pioglitazone to Reduce Small Increased Risk of Bladder Cancer. XXXX: European Medicines Agency, 2011.
18. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Last accessed 15 October 2011.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
22. Erdmann E, Song E, Spanheimer R, Van AR, De Bruyn T, Perez A. Pioglitazone and bladder malignancy during observational follow-up of proactive: 6-year update. Diabetes 2012. Conference: 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, PA, USA. 8-12 June 2012. Conference publication: (var. pagings) 61: A236.
23. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. Br Med J 2012; 344: e3645.
24. Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2012; 75: 254-259.
25. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-1962.
26. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
27. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. J Am Med Assoc 2011; 306: 737-745.
28. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-1481.
29. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-492.
30. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
31. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008; 31: 1455-1460.
32. Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008; 93: 666-673.